Second-generation antipsychotics

Reviewing the cost-effectiveness component of the CATIE trial

Robert Rosenheck, Marvin Swartz, Joseph Patrick McEvoy, T. Scott Stroup, Sonia Davis, Richard S.E. Keefe, John Hsiao, Jeffrey Lieberman

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

The cost-effectiveness component of the 18-month CATIE trial of schizophrenia ppharmacotherapy (n = 1460) showed that the first-generation antipsychotic pephenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.

Original languageEnglish (US)
Pages (from-to)103-111
Number of pages9
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume7
Issue number2
DOIs
StatePublished - Apr 1 2007

Fingerprint

Perphenazine
Antipsychotic Agents
Cost-Benefit Analysis
Intention to Treat Analysis
Haloperidol
Schizophrenia
Outcome Assessment (Health Care)
Therapeutics
Pharmaceutical Preparations
Tardive Dyskinesia

Keywords

  • Antipsychotics
  • Cost-effectiveness
  • Quality of life
  • Randomized trials schizophrenia

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this

Second-generation antipsychotics : Reviewing the cost-effectiveness component of the CATIE trial. / Rosenheck, Robert; Swartz, Marvin; McEvoy, Joseph Patrick; Stroup, T. Scott; Davis, Sonia; Keefe, Richard S.E.; Hsiao, John; Lieberman, Jeffrey.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 7, No. 2, 01.04.2007, p. 103-111.

Research output: Contribution to journalReview article

Rosenheck, Robert ; Swartz, Marvin ; McEvoy, Joseph Patrick ; Stroup, T. Scott ; Davis, Sonia ; Keefe, Richard S.E. ; Hsiao, John ; Lieberman, Jeffrey. / Second-generation antipsychotics : Reviewing the cost-effectiveness component of the CATIE trial. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2007 ; Vol. 7, No. 2. pp. 103-111.
@article{f9c964dd697d496ca4678d0bcc5878ed,
title = "Second-generation antipsychotics: Reviewing the cost-effectiveness component of the CATIE trial",
abstract = "The cost-effectiveness component of the 18-month CATIE trial of schizophrenia ppharmacotherapy (n = 1460) showed that the first-generation antipsychotic pephenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.",
keywords = "Antipsychotics, Cost-effectiveness, Quality of life, Randomized trials schizophrenia",
author = "Robert Rosenheck and Marvin Swartz and McEvoy, {Joseph Patrick} and Stroup, {T. Scott} and Sonia Davis and Keefe, {Richard S.E.} and John Hsiao and Jeffrey Lieberman",
year = "2007",
month = "4",
day = "1",
doi = "10.1586/14737167.7.2.103",
language = "English (US)",
volume = "7",
pages = "103--111",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Second-generation antipsychotics

T2 - Reviewing the cost-effectiveness component of the CATIE trial

AU - Rosenheck, Robert

AU - Swartz, Marvin

AU - McEvoy, Joseph Patrick

AU - Stroup, T. Scott

AU - Davis, Sonia

AU - Keefe, Richard S.E.

AU - Hsiao, John

AU - Lieberman, Jeffrey

PY - 2007/4/1

Y1 - 2007/4/1

N2 - The cost-effectiveness component of the 18-month CATIE trial of schizophrenia ppharmacotherapy (n = 1460) showed that the first-generation antipsychotic pephenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.

AB - The cost-effectiveness component of the 18-month CATIE trial of schizophrenia ppharmacotherapy (n = 1460) showed that the first-generation antipsychotic pephenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.

KW - Antipsychotics

KW - Cost-effectiveness

KW - Quality of life

KW - Randomized trials schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=34247567935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247567935&partnerID=8YFLogxK

U2 - 10.1586/14737167.7.2.103

DO - 10.1586/14737167.7.2.103

M3 - Review article

VL - 7

SP - 103

EP - 111

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 2

ER -